Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

GOSS

GOSS News

Newswire

12:54

Gossamer Bio shares surge 10.36% intraday as analysts boost price target and anticipate key clinical data in 2026.

06:44

Gossamer Bio's Price Target Rises to $9.50 Ahead of Critical Clinical Milestones

12:36

Gossamer Bio shares rise 10.59% intraday after Oppenheimer raises price target to $12 from $9 and maintains Outperform rating.

07:39

Gossamer Bio to Attend Investor Conferences in November

17:28

Gossamer Bio Reports Q3 2025 Results, Seralutinib Phase 3 Expected in 2026.

View More

About GOSS

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More